Modulating Lncrna NKILA in Tumor-Reactive T Cells to Enhance Their Trafficking to Breast Cancer by Inhibition of FasL-induced T-cell Apoptosis.

Di Huang,Shicheng Su,Erwei Song

DOI: https://doi.org/10.1200/jco.2017.35.7_suppl.143

IF: 45.3

2017-01-01

Journal of Clinical Oncology

Abstract:143 Background: Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the autologous tumor-reactive lymphocytes with direct anticancer activity. In addition to the effective application of ACT for cancer treatment to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors, many of the ACT therapy has failed because of the trafficking barrier of T cells. Methods: In vitro, we established tumor-reactive CTL by vaccination with autologous DCs pulsed with MUC1-derived peptides. Moreover, tumor-reactive T cells were transferred to the immunocompromised mice inoculated with autologous patient derived breast cancer xenografts (PDX). Results: In our study, we found that during the induction of tumor-reactive T cells, cytotoxic T lymphocytes (CTL) may undergo massive expansion and have the ability of specific lysis to tumor cells upon appropriate antigenic stimulation via NF-κB pathway activation. However, hyperactive tumor-specific lymphocytes were hypersensitivity to apoptosis signals in tumor milieu, such as Fas ligand. In this research, we showed that NKILA, an NF-κB interacting lncRNA, is up-regulated at the later phase of CTL activation. The up-regulated NKILA suppresses NF-κB activity and sensitizes T cells to apoptosis. In vivo, NKILA knockdown in tumor-reactive T cells upon transferring to the immunocompromised mice inoculated with autologous PDX enhances CTL in xenografts, and thus effectively inhibits tumor growth. Conclusions: Collectively, our findings suggested that NKILA upregulation is responsible for the apoptosis of tumor-responsive CTLs and targeting the lncRNA may provide a novel strategy to enhance the therapeutic efficacy of immune cell transferring for breast cancer.